Breaking News

Savient Provides Manufacturing Plans for Krystexxa

Savient Pharmaceuticals provided an update on its business activities related to the U.S. launch and commercialization of Krystexxa, a PEGylated uric acid specific enzyme for the treatment of chronic gout.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Savient Pharmaceuticals provided an update on its business activities related to the U.S. launch and commercialization of Krystexxa, a PEGylated uric acid specific enzyme for the treatment of chronic gout. The company is planning to launch the drug in 1Q11. For the launch of Krystexxa, Savient has inventory of the drug at its third party logistics warehouse in the U.S., which the company believes to be adequate to supply market demand through 1Q12. The company’s third party contract manufactu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters